BOYDSense

Exciting news: a €7M capital increase! 🚀 #SeriesA #MilestoneAchieved #NextChapter #Diabetesinnovation

🌟 Thank you from BOYDSense! 🌟 I am thrilled to share that BOYDSense last week had the incredible opportunity to participate in the #attd2024 Congress in Florence as a grant-winning company! 🎉 At this prestigious event, we showcased our innovative prototype of a breath glucose monitoring device at a Techfair booth, where we engaged with industry leaders and enthusiasts, sharing our latest advancements in diabetes management technology. Moreover, we had the privilege to present our groundbreaking science and publications at an oral poster session, further highlighting our commitment to pushing the boundaries of diabetes care. But that's not all - we were honored to take the stage not once, but twice, to discuss BOYDSense's latest progress and contributions to the field. The chance to share our vision and accomplishments with such a distinguished audience was truly invaluable. None of this would have been possible without the generous support of the #ATTD, and we extend our heartfelt gratitude to them for granting us this opportunity. We also want to express our sincere appreciation to the Diabetes Center Berne for their ongoing support and collaboration. Our experience at the ATTD Congress was nothing short of inspiring, and we are more motivated than ever to continue our mission of revolutionizing health monitoring powered by breath. Thank you to everyone who stopped by our booth, attended our presentations, and supported us along the way. Together, we are making strides towards a brighter, healthier future for individuals living with diabetes. #BOYDSense #DiabetesCare #ATTD2024 #Innovation #Techfair #Gratitude #Collaboration

🌟 Scientific News Alert! 🌟 We are thrilled to announce that BOYDSense will be participating in the upcoming ATTD Congress - the 17th International Conference on Advanced Technologies and Treatments for Diabetes! 🚀 🗓️ Save the Dates: March 6-9, 2024 📍 Location: Florence, Italy As a testament to our dedication and innovation in the field of diabetes management, BOYDSense has been selected as a startup grant winner, earning us a coveted spot at the Techfair Exhibition (Booth 55). 🏆 Join us on stage when we introduce our company, groundbreaking technology and latest scientific news on March 7th at 10:20. Our CEO`s session, titled "Breath Glucose Monitoring – Only Hot Air?", promises to be both enlightening and inspiring. 🔬 But the excitement doesn't stop there! On Saturday, March 9th, we will have the honor of speaking on the same topic during the Plenary Session at 11:38. 🎤 Additionally, don't miss Dr. Frank Flacke's presentation on the CHU clinical trial data during an oral poster presentation 08 (12.10-12.20) on Saturday as well. 📊   We are incredibly proud to showcase our advancements and contributions to the diabetes community at this prestigious event. Come visit our booth to learn more about BOYDSense and join us in shaping the future of diabetes care. See you in Florence! 🇮🇹 #ATTD2024 #DiabetesInnovation #BOYDSense #TechfairExhibition #MedicalTechnology #BenDelhey #FrankFlacke

Exciting News! BOYDSense Among Top 10 Finalists in Novo Nordisk's "Acteurs du Diabète" Innovation Contest! 🌟 We're thrilled to share that BOYDSense has not only participated but has also emerged as one of the 10 finalists in Novo Nordisk's prestigious "Acteurs du Diabète" innovation contest! 🏆✨ Out of an impressive pool of 36 candidates, Novo Nordisk has recognized BOYDSense's innovative solution for supporting patients in the management of diabetes as among the top 10. This acknowledgement shows our commitment to implement the most innovate technologies to make a positive impact for patients living with diabetes and pre diabetes. We are honored to be recognized as a key player in the quest for solutions that will effectively monitor type II diabetes, by a major global healthcare player. This is a great encouragement to continue our work and achieve our mission. A heartfelt thanks to Novo Nordisk for acknowledging our work. #BOYDSense #Innovation #DiabetesCare #ActeursDuDiabète #NovoNordisk #Top10Finalist 🚀💙

🚀 Help us win the #novonordisk Diabetes Challenge!   We are proud to share that BOYDSense was chosen for the next round of the Actors of Diabetes Challenge hosted by Novo Nordisk.  To make it to the top 10, we need your help! Currently, all projects are submitted to a Novo Nordisk jury and to a public vote.    Please support us and vote for BOYDSense on the link below until 4th of December! 🗳 To vote, each voter must create an account on the voting page (first name, last name, email address and password) and accept the general conditions and confidentiality policy. They will then have to select their profile (health professional or member of the public) and confirm their account by clicking on the link received by email. The voter will then have access to the details of the projects (summary + one pager or video) and will be able to give a “like” to their favorite project. https://lnkd.in/eeq3pU_u #novonordisk #diabetes #diabetesmanagement #vote

Meet our founder and CTO at #SEMI_MSEC in Arizona November 6th-8th! Bruno will Pitch our device, that simplifies the screening and monitoring of chronic conditions through breath.

Thanks to the Diabetes Center Berne, #BOYDSense has the opportunity to participate at #EASD2023 at the exhibition. At #BOYDSense we simplify the monitoring of chronic conditions through breath. Our first application under development is in Diabetes. If you like to know more, come and visits us at the DCB booth IZ006 #EASD2023 #Diabetes #DiabetesTechnology #DiabetesType2

The French channel France 3 dedicated a report on BOYDSense. The journalists also interviewed Prof. Pierre Gourdy, diabetes specialist within Toulouse CHU, who managed the clinical study conducted on 130 patients with Type-2 diabetes. See the replay on France 3 – August 30, 2023 (6:30 – Login required).